Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
17 Agosto 2023 - 9:00AM
Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced
the launch of an integrated bioreactor system that incorporates
Repligen XCell® ATF upstream intensification technology into
Sartorius’ Biostat STR® bioreactor, simplifying intensified seed
train and N perfusion implementation for biopharmaceutical
manufacturers. The Biostat STR® now contains a fully compatible
embedded XCell® ATF hardware and software module offering
predefined advanced control recipes with integrated Process
Analytical Technology (PAT). This system gives users a streamlined
way to control cell growth and improve cell retention in perfusion
processes without using a separate cell retention control tower.
In addition, customers can better utilize
facility space with a reduced equipment footprint from the
incorporation of the XCell® Controller hardware and software in the
Biobrain® automation platform, creating a single point of control
for 50 L – 2000 L upstream intensification processes. The single,
integrated controller provides easy integration into Supervisory
Control and Data Acquisition (SCADA) and Distributed Control
Systems (DCS).
“The market introduction of this integrated
bioreactor–intensification system created in partnership with
Repligen further reinforces Sartorius’ commitment to being an
innovator in process intensification and demonstrates our expertise
in upstream processing technologies,” said Mario Becker, Head of
Product Group Bioreactor Technologies, Sartorius. “Ultimately, our
goal is to help customers bring more therapeutics to patients
faster, and this launch advances our journey along that path to
enable continuous manufacturing.”
Customers are now able to easily purchase the
integrated system from Sartorius, with available pretested and
predefined configurations, resulting in faster delivery times than
engineered-to-order solutions.
Christine Gebski, Senior Vice President
Filtration & Chromatography at Repligen, said, “It’s been our
pleasure to partner with Sartorius on this program and to share
this milestone achievement. The successful pairing of our
market-leading XCell® ATF intensification control technology with
Sartorius’ single-use bioreactors provides end users with a
simplified, easy-to-implement perfusion-enabled bioreactor solution
for more efficient, higher density cell culture processes.”
This new integrated product offering builds on
Sartorius and Repligen Corporation’s aligned missions to enable the
development of new and better therapies and more affordable
medicine through expertise and collaboration.
URL: Sartorius Website,
Repligen Website
About Sartorius The Sartorius
Group is a leading international partner of life sciences research
and the biopharmaceutical industry. With innovative laboratory
instruments and consumables, the Lab Products & Services
division focuses on laboratories performing research and quality
control at pharmaceutical and biopharmaceutical companies as well
as academic research institutes. The Bioprocess Solutions division,
with its broad product portfolio focusing on single-use solutions,
helps customers manufacture biotech medications and vaccines
safely, rapidly, and economically. The company, based in
Goettingen, Germany, has a strong global reach with around 60
production and sales sites worldwide. Sartorius delivers
significant organic growth and regularly expands its portfolio
through the acquisition of complementary technologies. In fiscal
2022, the company generated sales revenue of around 4.2 billion
euros. At the end of 2022, around 16,000 employees were working for
customers around the globe. Follow Sartorius on LinkedIn.
About Repligen
CorporationRepligen Corporation is a life sciences tools
and technology company that develops and markets highly innovative
bioprocessing solutions and systems. Our products enable
efficiencies in the process of manufacturing a wide range of
biological drugs, including: monoclonal antibodies; recombinant
proteins; cell and gene therapies; and vaccines. We are inspiring
advances in bioprocessing for the customers we serve around the
globe; primarily biopharmaceutical companies and contract
development and manufacturing organizations (CDMOs). Our corporate
headquarters are located in Waltham, Massachusetts, with additional
administrative and manufacturing operations worldwide. The majority
of our manufacturing sites are located within the U.S. (California,
Massachusetts, New Jersey and New York), and outside of the U.S. we
have sites in Estonia, France, Germany, Ireland, the Netherlands
and Sweden. For more information about the company, see our website
at www.repligen.com and follow us on LinkedIn.
Repligen Forward-Looking
Statement The following constitutes a “Safe Harbor”
statement under the Private Securities Litigation Reform Act of
1995: This press release contains forward-looking statements, which
are made pursuant to the safe harbor provisions of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Investors are
cautioned that statements in this press release which are not
strictly historical statements, including, without limitation,
express or implied statements regarding Repligen’s partnership with
Sartorius, the impact of a single control system on Repligen’s end
users, and the future financial performance of Repligen constitute
forward-looking statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could”
and similar expressions. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated,
including, without limitation, risks associated with: our ability
to successfully grow our bioprocessing business, including as a
result of acquisition, commercialization or partnership
opportunities; our ability to successfully integrate any
acquisitions, our ability to develop and commercialize products and
the market acceptance of our products; reduced demand for our
products that adversely impacts our future revenues, cash flows,
results of operations and financial condition; our ability to
compete with larger, better financed bioprocessing, pharmaceutical
and biotechnology companies; our compliance with all Food and Drug
Administration and EMEA regulations; our volatile stock price; and
other risks detailed in Repligen’s most recent Annual Report on
Form 10-K on file with the Securities and Exchange Commission and
the other reports that Repligen periodically files with the
Securities and Exchange Commission. Actual results may differ
materially from those Repligen contemplated by these
forward-looking statements. These forward-looking statements
reflect management’s current views and Repligen does not undertake
to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the
date hereof except as required by law.
Contact SartoriusMaya
Fuerstenau-SharpHead of Marketing Cell Culture
TechnologiesBPSTradeMedia@Sartorius.com
Contact RepligenSondra S.
NewmanGlobal Head of Investor Relations(781)
419-1881Investors@Repligen.com
A photo accompanying this announcement is
available
athttps://www.globenewswire.com/NewsRoom/AttachmentNg/a3628d69-9ed6-4333-a9df-235c236201af
Repligen (NASDAQ:RGEN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Repligen (NASDAQ:RGEN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024